Table 2 Baseline characteristics of participants
SC | UT | |
|---|---|---|
(n = 24) | (n = 24) | |
Sex: female/male (%) | 10/14 (42/58) | 8/16 (33/67) |
age, mean (range) | 65 (45–78) | 64 (49–78) |
Disease duration, months since diagnosis (range) | 77 (2–144) | 63 (2–180) |
MDS-UPDRS-III score, mean (SD) | 37.9 (10.9) | 34.2 (14.2) |
Hoehn and Yahr stage: 2/3 (%) | 20/4 (83/17) | 22/2 (92/8) |
LEDD, mg (range) | 554 (200–1365) | 609 (0–1464) |
Patients not on dopaminergic therapy, n (%) | 0 (0) | 1 (4) |
Patients with Deep Brain Stimulation, n (%) | 1 (4) | 1 (4) |
Mini Mental State Examination score, mean (SD) | 29 (1) | 29 (1) |